The ITHANET virtual information day will be held virtually on September 29th 14:00 – 17:00 GMT+3.

Dear colleagues, friends, and the Sickle Cell Disease community, with profound sadness, we learned of the passing of Prof Kwaku Ohene-Frempong a giant in the Sickle Cell Disease field

The Committee for Medicinal Products for Human Use at the EMA adopted a positive opinion recommending marketing authorization for Oxbryta® for the treatment of haemolytic anaemia due to sickle cell disease (SCD) in patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.

The article “Newborn screening for sickle cell disease in Africa” has been published on the Lancet Haematology journal.It is focused on the newborn screening (NBS) for Sickle Cell Disease (SCD) just launched in Zambia.